Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Digital subtraction angiography

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Digital subtraction angiography. Displaying page 1 of 1.
    EudraCT Number: 2007-003263-52 Sponsor Protocol Number: BONN_Vaso07 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Bonn
    Full Title: Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in d...
    Medical condition: Comparision between two diagnostic methods (DSA and MRA) to evaluate supraaortale arteries using three different contrast mediums
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007683 Carotid angiography LLT
    9.1 10057784 MRI angiography LLT
    9.1 10065324 Digital subtraction angiography LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006014-41 Sponsor Protocol Number: Vasovist MA-01 Start Date*: 2008-04-14
    Sponsor Name:University Heidelberg, University Hospital Mannheim
    Full Title: Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Arte...
    Medical condition: Patients suffering from PAOD stage III or stage IV (confirmed by ECCM MRA, CTA, non-selective DSA, DUS) and have an indication for the evaluation of the entire lower leg axis down to the feet (comm...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002939 Aortoiliac occlusive disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002547-66 Sponsor Protocol Number: 308861 Start Date*: 2005-11-28
    Sponsor Name:Schering AG
    Full Title: Intra-individual open-label multicenter comparison study of magnetic resonance angiography (MRA) with the blood pool contrast agent Vasovist® and a conventional extracellular contrast agent with in...
    Medical condition: Patients who have aortoiliac disease Fontaine-stage IIb – IV and an indication for the evaluation of the infrarenal aorta and the peripheral run-off arteries (i.e. from infrarenal aorta to calves).
    Disease: Version SOC Term Classification Code Term Level
    7.1 10002939 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000449-15 Sponsor Protocol Number: DIONYSIUS Start Date*: 2020-12-11
    Sponsor Name:Amsterdam University Medical Centers, location AMC
    Full Title: Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
    Medical condition: Ischemic diabetic foot ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000994-69 Sponsor Protocol Number: SOV302 Start Date*: 2004-11-11
    Sponsor Name:Amersham Buchler GmbH & Co KG an affiliate of GE Healthcare Bio-Sciences
    Full Title: A multicentre, phase 3, open label study to assess the efficacy and safety of 0.1 mmol/kg Omniscan™ (gadodiamide injection) for Magnetic Resonance Angiography (MRA) of the aorto-iliac arteries
    Medical condition: Suspected or proven chronic PAOD predominantly located in the aorto-iliac region of Fontaine Stages IIb to IV (ie, Rutherford Stages I3-III), or presents with an ankle brachial pressure index of <0...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10062585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002721-18 Sponsor Protocol Number: AC-054-203 Start Date*: 2016-02-17
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A prospective, multi-center, open-label, single-arm, Phase 2 study to assess the efficacy and safety of clazosentan in reversing angiographically-confirmed cerebral vasospasm in adult subjects with...
    Medical condition: Aneurysmal subarachnoid hemorrhage (aSAH); cerebral vasospasm
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10047164 Vasospasm cerebral LLT
    19.1 100000004863 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000953-46 Sponsor Protocol Number: SOV301 Start Date*: 2004-10-13
    Sponsor Name:Amersham plc
    Full Title: A Multicentre, Phase 3, Open-Label, Controlled Study Evaluating the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) in Magnetic Resonance Angiography (MRA) of the Renal Arteries
    Medical condition: Renal artery stenosis (RAS) is implicated as the underlying cause in 1% to 5% of patients with hypertension and 5% to 15% of patients with end-stage renal disease entering dialysis programs each ye...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004521-17 Sponsor Protocol Number: BIT-001 Start Date*: 2018-02-19
    Sponsor Name:BIT Pharma GmbH
    Full Title: A Phase IIa: single ascending dose safety, tolerability and pharmacokinetic study of NicaPlant® in aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping
    Medical condition: Aneurysmal subarachnoid haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10008111 Cerebral haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002584-27 Sponsor Protocol Number: AC-054-301 Start Date*: 2007-11-07
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Aneurysmal subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042318 Subarachnoid haemorrhage NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) FI (Completed) SE (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) SI (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-006785-29 Sponsor Protocol Number: AC-054-302 Start Date*: 2009-09-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Subarachnoid aneurysmal hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    11 10042316 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) DE (Completed) SI (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002453-31 Sponsor Protocol Number: AC-054-201 Start Date*: 2005-02-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hem...
    Medical condition: Prevention of ischaemic complications related to vasospasm in patients with aneurysmal subarachnoid haemorrhage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) FI (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004068-21 Sponsor Protocol Number: PADHIF00805 Start Date*: 2006-01-11
    Sponsor Name:Genzyme Europe BV
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with ...
    Medical condition: Peripheral Arterial Disease (PAD) with no or poor Chronic Critical Limb Ischemia (CLI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005555-27 Sponsor Protocol Number: ESR-14-10473 Start Date*: 2017-09-12
    Sponsor Name:University Hospital Basel
    Full Title: Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A randomised multi-centre phase II trial comparing Ticagrelor versus Clopidogrel with outcome assessment on MRI (PR...
    Medical condition: Carotid artery stenting (CAS) is treatment for atherosclerotic carotid stenosis. The main adverse events are thromboembolic brain infarcts during the procedure. Ticagrelor, a novel reversible inhib...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 11:19:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA